Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRC
Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).
Eric Van Cutsem, MD, PhD, University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). He and his colleagues conducted the nonrandomized, phase IIIb CONSIGN study, in order to examine the effects of regorafenib in these previously treated patients.
After seeing the CORRECT study, which showed that regorafenib improves survival, the goal of the CONSIGN study was to include a larger number of patients, said Van Cutsem. The primary endpoint was to look at the safety of regorafenib and learn more about how to improve tolerance of the drug.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
